| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
|
Medicine details |
|
| Medicine name | regorafenib (Stivarga®) |
| Formulation | tablet |
| Reference number | 2219 |
| Indication | Monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/07/2017 |
| NICE guidance | TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |